Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Kirkland subject of alleged conflict in trade secrets clash

19 May 2026 In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties".

Americas

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme

19 May 2026 The award could rise to several billions under federal antitrust law, after the pharma company was found to have engaged in anticompetitive conduct over constipation drug Amitiza.

Americas

AbbVie’s trade secret suit against a Chinese rival gets green light

18 May 2026 A US court has refused to throw out AbbVie's claim that a former scientist brought its cancer drug secrets to a Chinese rival.